DAYPRO
What it isLong-acting COX-1 and COX-2 inhibitor; osteoarthritis and rheumatoid arthritis.
Why this oneIts unusually long persistence permits once-daily use but offers little flexibility when toxicity develops.
What limits it⚑ GI bleeding, kidney injury, cardiovascular events, and lithium elevation remain the main hazards.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Osteoarthritis | Adults | 1200 mg QD | 1200 mg QD | |
| Rheumatoid arthritis | Adults | 1200 mg QD | 1200 mg QD | |
| Juvenile rheumatoid arthritis | Peds 6-16 yr, by weight | 600 mg QD (22-31 kg); 900 mg QD (32-54 kg); 1200 mg QD (≥55 kg) | same | 1200 mg QD |
Renal Avoid in advanced renal disease unless benefits outweigh risk; monitor renal function in renal/hepatic impairment
Hepatic Undefined (monitor for hepatotoxicity; no specific dose adjustment stated)
Pregnancy Avoid at ~30 wks gestation or later (premature closure of fetal ductus arteriosus); limit use 20-30 wks (oligohydramnios/neonatal renal impairment)
Lactation Undefined
⚠ BOXED WARNINGS
Cost, est. cash$10–$300/month
Generic entry2001
Legacy pregnancy categoryMultiple / indication-, trimester- or formulation-dependent
Defining liabilityGI bleeding, kidney injury, hypertension and fluid retention; many agents increase lithium concentrations.

Open Oxaprozin in the interactive console ↗

